HIGHMARK COMMERCIAL MEDICAL POLICY - PENNSYLVANIA

 
 

Medical Policy:
I-285-001
Topic:
Fidanacogene elaparvovec-dzkt (Beqvez)
Section:
Injections
Effective Date:
June 3, 2024
Issued Date:
June 3, 2024
Last Revision Date:
May 2024
Annual Review:
May 2024
 
 

Fidanacogene elaparvovec-dzkt (Beqvez™) is a one-time gene replacement therapy indicated for the prevention of bleeding episodes in adult individuals with moderate-severe to severe hemophilia B. Hemophilia B is an X-linked genetic disorder characterized by a deficiency in clotting factor IX (FIX) resulting in impaired clotting. Severity of hemophilia B is determined based off the amount of FIX in the blood plasma.

Fidanacogene elaparvovec-dzkt (Beqvez) is an adeno-associated virus (AAV) gene therapy composed of a recombinant AAVRh74var viral capsid with a factor IX transgene. Expression of this transgene in liver cells yields functional human clotting high-activity FIX variant which is then secreted into circulation. 

Policy Position

Fidanacogene elaparvovec-dzkt (Beqvez) may be considered medically necessary when ALL the following criteria are met:

  • Individual is 18 of age or older at time of treatment decision; and
  • Documented diagnosis of moderate-severe or severe hemophilia B (ex. FIX levels less than 2 IU/dL) and
  • Prescribed by or in consultation with a hematologist or specialist with experience and expertise in the treatment of hemophilia B; and
  • Individual has been on prophylactic FIX replacement therapy for at least six (6) months prior to receiving gene therapy; and

o   Provider attestation of discontinuation of regular prophylactic FIX replacement therapy following appropriate timeframe for FIX levels to reach steady state after individual has received gene therapy; and

  • Individual has a current or historical life-threatening hemorrhage; or
  • Individual has repeated, serious spontaneous bleeding episodes; and
  • Individual has been tested for anti-AAVRh74var antibodies and is deemed a suitable candidate for treatment; and
  • Individual does not have ANY of the following:
    • No previous documented history of neutralizing antibodies to exogenous FIX including the use of bypassing agents (such as recombinant FVIIa and activated prothrombin complex concentrate [aPCC]); or
    • Active infection with hepatitis B or C; or
    • History of hepatitis B or C exposure currently controlled by antiviral therapy; or
    • Diagnosis of HIV not currently controlled by antiviral therapy; or
    • Liver function levels (hepatic aminotransferases [AST and ALT], total bilirubin, and alkaline phosphatase) greater than or equal to two (2) times upper limit of normal; or
    • History of arterial or recurrent or unprovoked venous thromboembolic events (e.g., non- hemorrhagic stroke, pulmonary embolism, myocardial infarction, arterial embolus); and
  • Acute factor product utilized prior to receiving gene therapy to be maintained for treatment of on-demand bleeds or perioperative management; and
  • The requesting physician shall provide continual clinical outcome information within a provider portal as requested by Highmark; and
  • If the member changes providers, the member will notify Highmark of the member’s new provider contact information.  The member will allow Highmark the continuous ability to receive information pertaining to clinical outcomes of this therapy from the member’s current and future providers.

Note: Highmark’s receipt of clinical outcome information shall not impact a member’s eligibility, benefits, premiums, or cost-sharing obligations under the terms of the member’s insurance contract.

Note: The safety and effectiveness of repeat administration of fidanacogene elaparvovec-dzkt (Beqvez) has not been evaluated. Therefore, coverage will be limited to once per lifetime.

The use of fidanacogene elaparvovec-dzkt (Beqvez) not meeting the criteria as indicated in this policy is considered not medically necessary. 

J3590

 

 

 

 

 

 




NOTE: In addition to the above criteria, product specific dosage and/or frequency limits may apply in accordance with the U.S. Food and Drug Administration (FDA)-approved product prescribing information, national compendia, Centers for Medicare and Medicaid Services (CMS) and other peer reviewed resources or evidence-based guidelines. Highmark may deny, in full or in part, reimbursement for utilization that does not fall within the applicable dosage and/or frequency limits.


D67

 

 

 

 

 

 



Place of Service: Outpatient

Fidanacogene elaparvovec-dzkt (Beqvez) is typically an outpatient procedure which is only eligible for coverage as an inpatient procedure in special circumstances, including, but not limited to, the presence of a co-morbid condition that would require monitoring in a more controlled environment such as the inpatient setting. is typically an outpatient procedure which is only eligible for coverage as an inpatient procedure in special circumstances, including, but not limited to, the presence of a co-morbid condition that would require monitoring in a more controlled environment such as the inpatient setting.


The policy position applies to all commercial lines of business



Links






This policy is designed to address medical guidelines that are appropriate for the majority of individuals with a particular disease, illness, or condition. Each person's unique clinical or other circumstances may warrant individual consideration, based on review of applicable medical records, as well as other regulatory, contractual and/or legal requirements.

Medical policies do not constitute medical advice, nor are they intended to govern the practice of medicine. They are intended to reflect Highmark's reimbursement and coverage guidelines. Coverage for services may vary for individual members, based on the terms of the benefit contract.

Highmark retains the right to review and update its medical policy guidelines at its sole discretion. These guidelines are the proprietary information of Highmark. Any sale, copying or dissemination of the medical policies is prohibited; however, limited copying of medical policies is permitted for individual use.

Discrimination is Against the Law
The Claims Administrator/Insurer complies with applicable Federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, or sex. The Claims Administrator/Insurer does not exclude people or treat them differently because of race, color, national origin, age, disability, or sex. The Claims Administrator/ Insurer:

  • Provides free aids and services to people with disabilities to communicate effectively with us, such as:
    • Qualified sign language interpreters
    • Written information in other formats (large print, audio, accessible electronic formats, other formats)
  • Provides free language services to people whose primary language is not English, such as:
    • Qualified interpreters
    • Information written in other languages

If you need these services, contact the Civil Rights Coordinator.

If you believe that the Claims Administrator/Insurer has failed to provide these services or discriminated in another way on the basis of race, color, national origin, age, disability, or sex, you can file a grievance with: Civil Rights Coordinator, P.O. Box 22492, Pittsburgh, PA 15222, Phone: 1-866-286-8295, TTY: 711, Fax: 412-544-2475, email: CivilRightsCoordinator@highmarkhealth.org. You can file a grievance in person or by mail, fax, or email. If you need help filing a grievance, the Civil Rights Coordinator is available to help you.

You can also file a civil rights complaint with the U.S. Department of Health and Human Services, Office for Civil Rights electronically through the Office for Civil Rights Complaint Portal, available at https://ocrportal.hhs.gov/ocr/portal/lobby.jsf, or by mail or phone at:

U.S. Department of Health and Human Services
200 Independence Avenue, SW
Room 509F, HHH Building
Washington, D.C. 20201
1-800-368-1019, 800-537-7697 (TDD)

Complaint forms are available at http://www.hhs.gov/ocr/office/file/index.html.

This information is issued by Highmark Blue Shield on behalf of its affiliated Blue companies, which are independent licensees of the Blue Cross Blue Shield Association.  Highmark Inc. d/b/a Highmark Blue Shield and certain of its affiliated Blue companies serve Blue Shield members in the 21 counties of central Pennsylvania. As a partner in joint operating agreements, Highmark Blue Shield also provides services in conjunction with a separate health plan in southeastern Pennsylvania.  Highmark Inc. or certain of its affiliated Blue companies also serve Blue Cross Blue Shield members in 29 counties in western Pennsylvania, 13 counties in northeastern Pennsylvania, the state of West Virginia plus Washington County, Ohio, the state of Delaware[ and [8] counties in western New York and Blue Shield members in [13] counties in northeastern New York].  All references to Highmark in this document are references to Highmark Inc. d/b/a Highmark Blue Shield and/or to one or more of its affiliated Blue companies.





Medical policies do not constitute medical advice, nor are they intended to govern the practice of medicine. They are intended to reflect reimbursement and coverage guidelines. Coverage for services may vary for individual members, based on the terms of the benefit contract.

Discrimination is Against the Law
The Claims Administrator/Insurer complies with applicable Federal civil rights laws and does not discriminate on the basis of race, color, national origin, age, disability, or sex. The Claims Administrator/Insurer does not exclude people or treat them differently because of race, color, national origin, age, disability, or sex. The Claims Administrator/ Insurer:

  • Provides free aids and services to people with disabilities to communicate effectively with us, such as:
  • Qualified sign language interpreters
  • Written information in other formats (large print, audio, accessible electronic formats, other formats)

  • Provides free language services to people whose primary language is not English, such as:
  • Qualified interpreters
  • Information written in other languages
  • If you need these services, contact the Civil Rights Coordinator.

    If you believe that the Claims Administrator/Insurer has failed to provide these services or discriminated in another way on the basis of race, color, national origin, age, disability, or sex, you can file a grievance with: Civil Rights Coordinator, P.O. Box 22492, Pittsburgh, PA 15222, Phone: 1-866-286-8295 , TTY: 711, Fax: 412-544-2475, email: CivilRightsCoordinator@highmarkhealth.org. You can file a grievance in person or by mail, fax, or email. If you need help filing a grievance, the Civil Rights Coordinator is available to help you.

    You can also file a civil rights complaint with the U.S. Department of Health and Human Services, Office for Civil Rights electronically through the Office for Civil Rights Complaint Portal, available at https://ocrportal.hhs.gov/ocr/portal/lobby.jsf, or by mail or phone at:

    U.S. Department of Health and Human Services
    200 Independence Avenue, SW
    Room 509F, HHH Building
    Washington, D.C. 20201
    1-800-368-1019, 800-537-7697 (TDD)

    Complaint forms are available at http://www.hhs.gov/ocr/office/file/index.html.